# A Study to Assess the Safety and Efficacy of Different Doses of ELV001 to Treat Active Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate and Tumor Necrosis Factor Inhibition (START SYNERGY)

> **NCT07409103** · PHASE2 · RECRUITING · sponsor: **Elevara Medicines Limited** · enrollment: 180 (estimated)

## Conditions studied

- Active Rheumatoid Arthritis

## Interventions

- **DRUG:** ELV001 25 mg
- **DRUG:** ELV001 75 mg
- **DRUG:** ELV001 125 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07409103
- **Lead sponsor:** Elevara Medicines Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-18
- **Primary completion:** 2027-04-15
- **Final completion:** 2028-03-31
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2026-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07409103

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07409103, "A Study to Assess the Safety and Efficacy of Different Doses of ELV001 to Treat Active Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate and Tumor Necrosis Factor Inhibition (START SYNERGY)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07409103. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*